Navigation Links
Marrone Bio Innovations Files Patent for a Unique Bacillus Species
Date:3/27/2013

Davis, CA (PRWEB) March 27, 2013

Marrone Bio Innovations, Inc. (MBI) a leading global provider of natural pest management products for the agricultural and water treatment markets, announces the submission of a patent application encompassing a new Bacillus sp. strain F727, to the United States Patent and Trademark Office. This strain was first discovered from soil collected in California by one of MBI’s employees. The chemistry and genetic profiles appear to be unique from other known Bacillus species. In addition, the anti-fungal compounds produced by this new strain are different than the current commercial Bacillus biofungicide products.

In comparison tests with commonly used chemical fungicides, the Bacillus sp. strain F727 shows a high level of activity against a broad range of fungal and bacterial plant pathogens. In MBI’s greenhouse tests, Bacillus strain F727 outperformed the leading Bacillus biofungicides on the market, particularly on downy mildews, which are difficult to control with both chemicals and biofungicides.

According to Phyllis Himmel, Ph.D., MBI Vice President of Research & Development, Bacillus sp. strain F727 shows consistent fungicidal activity against Botrytis gray mold and downy mildews in plant tests. “We are excited to move this candidate to field trials on a broad range of crops in 2013,” she said. “The strain has also shown activity beyond plant disease control. Additional work is in progress to explore its usefulness as a plant growth promoter in crops such as corn, soybeans, tomatoes and turf.”

Hector Absi, MBI’s Sr. VP of Commercial Operations, stated, “I am excited to have another MBI fungicide/bactericide to enhance our current commercial product, Regalia®. We believe the combination of the two products will provide superior disease control and plant health across a broad range of crops.”

###

About Marrone Bio Innovations
Marrone Bio Innovations, Inc. (MBI) is a leading global provider of biopesticides for the agricultural and water treatment markets. MBI's award-winning products include Regalia® biofungicide, Grandevo®, a broad-spectrum bioinsecticide and Zequanox® the first biological product to selectively control invasive zebra and quagga mussels. MBI has also developed a pipeline of products including several nematicide, fungicide, algaecide and plant health product candidates. The company currently has more than 150 patents pending in the U.S. and internationally.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10577112.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Marrone Bio Innovations Submits New Bioherbicide for EPA Registration
2. Marrone Bio Innovations’ Zequanox® Demonstrates Control of Zebra Mussels in Illinois Lake
3. Marrone Bio Innovations’ CEO to Address European Biopesticide Industry at Informa Life Sciences Biopesticides Conference
4. Marrone Bio Innovations Breaks Ground on Michigan Manufacturing Facility
5. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
6. BioHealth Innovation, Inc. Forms Commercial Relevance Advisory Board to Help Advance Market-Relevant Innovations in Central Maryland
7. Genomic Health Announces Results from Two Studies Demonstrating Innovations in Next Generation Sequencing From Paraffin Tissue, Enhancing Understanding of Tumor Biology
8. Brain Research Foundation 2013 Scientific Innovations Awards To Dr. Jean Hebert and Dr. Brian Litt
9. Prism Awards Honor Innovations in ‘Ubiquitous’ Photonics Technology
10. LATISTA Announces Next-Generation iPad App 2.0 for Construction with Industry Leading Innovations
11. Wake Forest Innovations Partners with Veterinary Bioscience Institute to Develop Educational Programs for Life Science Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life ... for the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan ... The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary ...
Breaking Biology Technology:
(Date:5/6/2017)... 5, 2017 RAM Group , ... new breakthrough in biometric authentication based on a ... properties to perform biometric authentication. These new sensors are ... created by Ram Group and its partners. This sensor ... supply chains and security. Ram Group is a ...
(Date:4/17/2017)... 17, 2017 NXT-ID, Inc. (NASDAQ: NXTD ... filing of its 2016 Annual Report on Form 10-K on Thursday ... ... available in the Investor Relations section of the Company,s website at ... website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Biology News(10 mins):